Earnings Releases·Nov 13, 2026, 5:27 PM ET

BeyondSpring — Third Quarter 2026 Earnings Summary

Reported a net loss of $2.1 million for the quarter ended September 30, 2026, compared to a $1.6 million loss in the prior year period; however, net income attributable to BeyondSpring Inc. was $50.8 million for the quarter and $47.8 million year-to-date, driven by a $53.7 million gain on the sale of a subsidiary.
Shareholders' equity turned positive to $15.2 million as of September 30, 2026, reversing a $32.2 million deficit from December 31, 2025, while cash and short-term investments declined to $0.6 million from $4.0 million.
The company's lead asset, Plinabulin, received FDA Fast Track designation for the combination with docetaxel in advanced non-squamous NSCLC patients without actionable genomic alterations who have progressed after anti-PD-(L)1 therapy and platinum-based chemotherapy.
Management aims to advance the DUBLIN-4 trial toward a prespecified interim analysis at 221 progression-free survival events, supported by a strategic transaction where Biolin Investment Limited will fund approximately half of the China portion of the 442-patient enrollment.
Revenue remained $0 for the quarter and year-to-date periods, and the company continues to pursue financing and strategic opportunities to support global trial execution and address risks related to listing requirements.